Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

• Status: Recruiting
• Trial end date: 2022-06-15
• Target enrollment: 0
• Participant gender: All

Summary

This is an exploratory study designed to generate preliminary data in evaluating the efficacy of Nucala in the treatment of chronic spontaneous urticaria.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Male and female patients 18 years or older.

• Clinical and/or histopathological diagnosis of conventional CSU

• Unresponsive to oral antihistamine therapy

• Good general health as confirmed by medical history

• Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and

• Patients who read and sign an approved informed consent for this study

Exclusion Criteria:

• Vulnerable study population

• Pregnant or nursing women

• Women planning a pregnancy within the study period

• Current or previous Xolair use

• Biopsy proven neutrophilic rich urticaria

• Known history of adverse reaction to Nucala

• Severe asthma requiring high-dose inhaled or systemic corticosteroids